Transposons have emerged as promising vectors for gene therapy that can potentially
overcome some of the limitations of commonly used viral vectors. Transposons stably …

To improve clinical outcomes and shorten the vein-to-vein time of chimeric antigen receptor
T (CAR-T) cells, we developed the FasT CAR-T (F-CAR-T) next-day manufacturing platform …

Since the introduction of the use of chimeric antigen receptor T-cell therapy (CAR-T therapy)
dramatically changed the therapeutic strategy for B cell tumors, various CAR-T cell products …

Effective control of non-small-cell lung cancer (NSCLC) remains clinically challenging,
especially during advanced stages of the disease. This study developed an adoptive T-cell …

Clinical trials of CD19-specific chimeric antigen receptor (CAR19) T cells have
demonstrated remarkable efficacy against relapsed and refractory B cell malignancies. The …

DNA transposons and retroviruses are versatile tools in functional genomics and gene
therapy. To facilitate their application, we conducted a genome-wide insertion site profiling …

Simple Summary We used fresh or thawed Umbilical Cord Blood (UCB) to produce CAR-T
cells directed against CD123, and we compared their functionality to Peripheral Blood (PB) …

Relapsed/refractory acute lymphoblastic leukemia (ALL) has a low remission rate after
chemotherapy, a high relapse rate and poor long-term survival even when allogeneic …

In the 1990s, the application of immunotherapy approaches to target cancer cells resulted in
significant clinical responses in patients with advanced malignancies who were refractory to …

CD19-specific chimeric antigen receptor (CAR19) T cells, generated using viral vectors, are
an efficacious but costly treatment for B cell malignancies. The nonviral piggyBac …